BRAF and non-small cell lung carcinoma: However, its great impact was recently valued in NSCLC [60] when a liquid biopsy was applied for analysis of “druggable” abnormalities such as mutations in EGFR [118] and BRAF [119] genes, as well as ALK and ROS1 rearrangements [120] or MET amplification [121].